• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Chronic kidney disease and the outcomes of fibrinolysis for ST-segment elevation myocardial infarction: A real-world study
by Wuxiang Xie, Anushka Patel, Eric Boersma, Lin Feng, Min Li, Runlin Gao, Yangfeng Wu BackgroundIn low-resource regions, fibrinolytic therapy is often the only option for ST-elevation myocardial infarction (STEMI) patients as primary percutaneous coronary intervention (PCI) is often not available and patients are hardly transferred to a medical center with PCI capacity within the first 120 minutes. Chronic kidney disease (CKD) is one of the most frequently encountered complications of STEMI. However, the evidence for the efficacy of fibrinolytic therapy in STEMI patients with CKD is still limited. The aim of this study is...
Source: PLoS One - January 19, 2021 Category: Biomedical Science Authors: Wuxiang Xie Source Type: research

Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020.
CONCLUSIONS Telemedicine reduced the delay time of STEMI patients during the COVID-19 pandemic. The difference in short-term adverse clinical outcomes was not statistically significant between patients who used the app and those who did not. PMID: 32938901 [PubMed - in process]
Source: Medical Science Monitor - September 18, 2020 Category: Research Tags: Med Sci Monit Source Type: research

Can Clinical and Functional Outcomes Be Improved with an Intelligent “Internet Plus”-Based Full Disease Cycle Remote Ischemic Conditioning Program in Acute ST-elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention? Rationale and Design of the i-RIC Trial
DiscussionThe i-RIC trial is designed to test the hypothesis that clinical and functional outcomes can be improved with the i-RIC program in STEMI patients undergoing PCI. The concept of RIC is expected to be enhanced with this intelligent “Internet Plus”-based program focusing on the full disease cycle. If the i-RIC program results in superior improvement in primary and secondary outcomes, it will offer an innovative treatment option for STEMI patients and form the basis of future recommendations.Clinical Trial RegistrationChinese Clinical Trial Registry (http://www.chictr.org.cn): ChiCTR2000031550, 04 April 2020.
Source: Cardiovascular Drugs and Therapy - June 29, 2020 Category: Cardiology Source Type: research

Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study
ConclusionMMACS patients with insufficient DAPT management experienced relatively more ischemic events. DAPT for at least 1  year may be beneficial to this special population without significantly increasing the bleeding risks.Trial registrationClinicalTrials.gov identifier, NCT01735305.
Source: Advances in Therapy - May 15, 2020 Category: Drugs & Pharmacology Source Type: research

Circulating microRNAs as biomarkers for severe coronary artery disease
This study aimed to evaluate the diagnostic value of circulating microRNAs (miRNAs) in patients with severe CAD requiring PCI. The plasma miRNA profiles were determined using miRNA microarray. The relative expression levels of differentially expressed miRNA were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Nine miRNAs (ebv-miR-BART12, ebv-miR-BART16, let-7i-5p, miR-130a-3p, miR-26a-5p, miR-3149, miR-3152–3p, miR-32-3p, and miR-149-3p) were differentially expressed between severe CAD and control groups. Four miRNAs (let-7i-5p, miR-32-3p, miR-3149, and miR-26a-5p) validated by qRT-PCR...
Source: Medicine - April 1, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention
ConclusionChinese herbal medicines plus western medicine standard therapy improved clinical outcomes in patients with ACS and mild-to-moderate renal insufficiency. Additionally, this study also demonstrated Chinese herbal medicines were useful in deferring decline of renal function.Graphical abstract
Source: Journal of Ethnopharmacology - November 3, 2019 Category: Drugs & Pharmacology Source Type: research

Obesity is associated with worse long-term outcomes in hypertrophic cardiomyopathy patients with acute myocardial infarction.
CONCLUSION: Acute myocardial infarction and hypertrophic cardiomyopathy patients who were obese exhibited worse long-term outcomes than those without obesity. PMID: 31674878 [PubMed - as supplied by publisher]
Source: Perfusion - October 31, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Yang J, Wang L, Sun T, Guo Q, Liu F, Zhou Y Tags: Perfusion Source Type: research

Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention
ConclusionLp(a) is an independent predictor of the prevalence of more complex coronary artery lesions (SYNTAX score ≥ 23) in patients with PCI. In addition, our study has shown that Lp(a) has no relationship with long-term cardiovascular outcomes in Chinese patients with PCI.
Source: Nutrition, Metabolism and Cardiovascular Diseases - September 27, 2019 Category: Nutrition Source Type: research

Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5-year follow-up retrospective cohort study.
Conclusions: Warfarin reduces the incidence of MACCEs but does not increase bleeding events in Chinese patients with AF who underwent PCI. For patients taking warfarin, recurrent myocardial infarction and a baseline CHA2DS2-VASc score >4 were related to MACCE occurrence. PMID: 31144555 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 1, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective
ConclusionsThere was considerable unexplained variation in contemporary costs for all major cardiovascular events. One emerging theme was that average costs in the USA were considerably higher than anywhere else.
Source: PharmacoEconomics - April 3, 2019 Category: Health Management Source Type: research

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
ConclusionsThe patients in the non-PPI group were observed to be associated with less risk of MACE, myocardial infarction recurrence, stent thrombosis, target vessel revascularization (TVR) and stroke. And the two groups had similar all cause death, cardiovascular death, bleedings events.
Source: IJC Heart and Vasculature - April 2, 2019 Category: Cardiology Source Type: research

Impact of anemia on percutaneous coronary intervention in Chinese patients: A large single center data
ConclusionsPre ‐PCI anemia was not an independent risk factor of any adverse clinical events, while post‐PCI anemia had a predictable value of MI, TVR, and MACE after PCI.
Source: Journal of Interventional Cardiology - December 5, 2018 Category: Cardiology Authors: Lin Jiang, Zhan Gao, Ying Song, Jingjing Xu, Xiaofang Tang, Huanhuan Wang, Ru Liu, Ping Jiang, Bo Xu, Jinqing Yuan Tags: ORIGINAL INVESTIGATION Source Type: research

Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Abstract PURPOSE: Monotherapy with either aspirin or clopidogrel is recommended for long-term use after discontinuation of dual-antiplatelet therapy (DAPT) for acute coronary syndrome (ACS) management after percutaneous coronary intervention (PCI). The present study is to evaluate the cost-effectiveness of clopidogrel versus aspirin after 12-month DAPT for patients with ACS who underwent PCI in China. METHODS: A 2-part model was developed to estimate the cost-effectiveness of clopidogrel compared with aspirin. The short-term part was a decision tree that included health states such as myocardial infarction (M...
Source: Clinical Therapeutics - November 20, 2018 Category: Drugs & Pharmacology Authors: Zhang L, Lin Z, Yin H, Liu J, Xuan J Tags: Clin Ther Source Type: research

Pages: 1  2  3  4  5  6  7  8